Pilot Study of Oral Colchicine for Preventing Graft Failure After Coronary Artery Bypass Surgery A Single Center Phase 4 Randomized Trial

What this Trial Is About

Researchers are evaluating the preliminary effect of oral colchicine therapy on graft outcomes in patients who have undergone primary isolated coronary artery bypass grafting CABG. The trial aims to determine if colchicine can reduce graft failure after CABG and whether it is feasible to conduct a larger, multicenter trial to test this hypothesis. Participants will be randomly assigned to receive either oral colchicine at a dose of 0.5 mg daily for 12 months or no colchicine therapy. The treatment period lasts for one year following CABG. Clinical follow-up visits are scheduled at 1 month, 6 months, and 12 months after the surgery. Additionally, participants will undergo coronary computed tomography angiography CCTA scans at one week and 12 months post-CABG. During the study, participants will be monitored through clinical evaluations and imaging tests to assess graft status and cardiovascular events. The primary outcome measured is the graft failure rate at one year post-CABG. Secondary outcomes include the time to the first major adverse cardiovascular event within one year and the rate of new perioperative atrial fibrillation within one week after surgery. Participants will be followed for the full 12 months to evaluate these outcomes.

Pilot Trial of Colchicine for Graft Failure in CABG